# Delaware Governor Signs Bill Allowing Medical Cannabis Use for Terminally Ill Patients in Hospitals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/delaware-governor-signs-bill-allowing-medical-cannabis-use-for-terminally-ill-patients-in-hospitals/ > **Published:** 2026-05-26T09:14:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:53:52-04:00 > **Clinical Summary:** Delaware now allows cannabis for terminal patients in hospitals. Clinical guidance on palliative care integration, dosing, and safety monitoring. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Terminally IllHospitalsHempTHCRegulation Why This Matters Delaware’s legalization of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) for terminally ill hospitalized patients establishes a legal framework for clinicians to consider cannabis as a palliative option in end-of-life care, potentially improving symptom management for pain, nausea, and anxiety in this population. This policy change requires clinicians to develop institutional protocols for prescribing, administration, and monitoring of cannabis in hospital settings, as well as to engage in informed consent discussions with eligible patients and families about efficacy and risks. The regulatory clarity provided by this bill reduces legal liability concerns for healthcare providers while creating an evidence gap that clinicians must address through careful documentation and outcome tracking to build the clinical knowledge base for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in terminal illness. Clinical Summary Delaware’s newly signed legislation permits terminally ill patients to access medical cannabis within hospital settings, expanding end-of-life care options in a state with an existing medical cannabis program. This policy change addresses a significant gap in palliative and hospice care by allowing patients with terminal diagnoses to use cannabis for symptom management, pain relief, and comfort during their final stages of illness, even in institutional healthcare environments where [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) was previously restricted. The law effectively removes barriers that previously prevented dying patients from accessing a treatment modality that may provide meaningful symptom relief when conventional options are limited or inadequate. Clinicians caring for terminally ill patients in Delaware hospitals can now discuss cannabis as part of a comprehensive end-of-life care plan, potentially improving [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) and patient autonomy in their final days. For physicians, this legislation clarifies the legal landscape and reduces liability concerns when patients request or might benefit from [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in hospital-based palliative settings. Clinicians should remain informed about their state’s specific regulations on cannabis in institutional settings and consider discussing this option with eligible terminally ill patients as part of comprehensive end-of-life conversations. Dr. Caplan’s Take “What Delaware has done here is clinically sound: we now have the ability to offer cannabinoids to dying patients in a hospital setting where we can monitor them properly, titrate dosing, and document outcomes, which is exactly how medicine should work rather than forcing patients to seek unregulated products outside the hospital walls.” Clinical Perspective Delaware’s legalization of medical cannabis for terminally ill hospitalized patients represents a pragmatic policy shift that clinicians should understand, though the clinical evidence base remains limited and heterogeneous across patient populations and cannabinoid formulations. While some patients report symptom relief for pain, nausea, and anxiety in end-of-life care, the lack of standardized dosing, variable product quality, and potential drug interactions—particularly with opioids and sedatives commonly used in palliative settings—warrant careful consideration before implementation. Clinicians should be aware that the concurrent regulatory discussions around [hemp-derived THC](https://cedclinic.com/hemp-derived-thc-products-regulation-patient-access/) products may create confusion about product standardization and safety profiles between hospital-grade and commercially available preparations. For practitioners in Delaware hospitals, this development necessitates developing clear protocols around patient selection, informed consent discussions acknowledging limited evidence, and coordination with palliative care teams to monitor for adverse effects and interactions. Until more robust clinical data emerge, 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Delaware%20Governor%20Signs%20Bill%20Allowing%20Medical%20Cannabis%20Use%20for%20Terminally%20Ill%20Patients%20in%20Hospitals%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56518)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56518)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Delaware%20Governor%20Signs%20Bill%20Allowing%20Medical%20Cannabis%20Use%20for%20Terminally%20Ill%20Patients%20in%20Hospitals%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56518)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://hempgazette.com/news/delaware-medical-cannabis-hospitals-bill-signed/](https://hempgazette.com/news/delaware-medical-cannabis-hospitals-bill-signed/) Further Reading CED Clinic Blog[The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`](https://cedclinic.com/fda-breakthrough-therapy-ver-01-cannabis-chronic-back-pain/) Evidence Watch[Cannabis Use in Pregnancy Linked to Child Behavioral Outcomes: A Study on Autism Spectrum Disorder](https://cedclinic.com/peripregnancy-cannabis-exposure-child-development/) Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).